Business Strategy & Outlook:
Israel-based Teva Pharmaceutical is one of the largest global generic drug manufacturers, with a significant presence in the United States and in Western Europe. Generic drug manufacturers with large exposure to the U.S. have fared very poorly compared with the overall market over the past few years due to factors that resulted in a highly deflationary generic drug price environment. To combat further margin deterioration, the largest, most capable manufacturers have invested more heavily in development and marketing of complex generics and biosimilars, which face much less competition and price erosion than small-molecule generics.
Founded in 1901, Teva was a small wholesale drug business in Jerusalem that converted into a local drug manufacturer during World War II with the rise in demand. The company consolidated the market in 1960 to create the largest drugmaker; it later expanded into Europe and the U.S. and then into generics in 1984 with the passage of the Hatch-Waxman Act. In the following 30 years, Teva completed roughly 30 acquisitions to further its position as the largest global generic manufacturer with roughly 90 manufacturing and research and development facilities worldwide. Despite efforts to curb margin deterioration by eliminating unprofitable drugs in the portfolio, Teva’s top and bottom lines have been negatively affected by a 70% decline in sales for its largest specialty drug, Copaxone, following generic entry and competition from new therapies. At its peak in 2013, Copaxone generated $4.3 billion in sales and contributed one fifth of total company revenue. While the company’s specialty drug pipeline is deep and consists of several novel biologic products and biosimilars, the growth is expected to be anemic over the next few years with slow generic revenue growth and a further decline in Copaxone sales. The company forecasts $750 million in Copaxone revenue in 2022.
Financial Strengths:
As of year-end 2021, Teva holds net debt of $20.9 billion, with $1.4 billion due in 2022, $2.1 billion due in 2023, and $2.0 billion due in 2024. The company’s $2 billion in cash and free cash flow generated from operations gives us some assurance that Teva should meet its obligations in the near term. Legal risk from ongoing litigation related to opioids, price-fixing, and Copaxone is also a risk to liquidity over the next several years. The base assumption calls for $2 billion in a cash settlement paid over a period of 15 years.
Bulls Say:
- As a leading global generic manufacturer, Teva enjoys economies of scale over its smaller peers.
- Teva’s specialty portfolio represents one fifth of sales and diversifies the company from generic drug deflation risk.
- Teva’s biosimilar for Humira is anticipated to launch in the U.S. in 2023, which should bolster specialty segment sales.
Company Description:
Based in Israel, Teva is one of the world’s largest generic drug manufacturers, with over 3,500 products marketed in over 60 countries. While a majority of its revenue is attributed to prescription generic drugs, Teva develops and markets its own branded specialty and biopharmaceutical products, primarily in the U.S. and in Europe. The company’s branded portfolio generates one fifth of total revenue and consists of patented therapies targeting central nervous system conditions (Austedo, Ajovy, Copaxone), oncology (Bendeka/Treanda), and respiratory conditions (ProAir, Qvar). While global competition has facilitated the commodification of small-molecule generic drugs, Teva’s portfolio rationalization has resulted in less overall price erosion versus peers.
(Source: Morningstar)
DISCLAIMER for General Advice: (This document is for general advice only).
This document is provided by Laverne Securities Pty Ltd T/as Laverne Investing. Laverne Securities Pty Ltd, CAR 001269781 of Laverne Capital Pty Ltd AFSL No. 482937.
The material in this document may contain general advice or recommendations which, while believed to be accurate at the time of publication, are not appropriate for all persons or accounts. This document does not purport to contain all the information that a prospective investor may require. The material contained in this document does not take into consideration an investor’s objectives, financial situation or needs. Before acting on the advice, investors should consider the appropriateness of the advice, having regard to the investor’s objectives, financial situation, and needs. The material contained in this document is for sales purposes. The material contained in this document is for information purposes only and is not an offer, solicitation or recommendation with respect to the subscription for, purchase or sale of securities or financial products and neither or anything in it shall form the basis of any contract or commitment. This document should not be regarded by recipients as a substitute for the exercise of their own judgment and recipients should seek independent advice.
The material in this document has been obtained from sources believed to be true but neither Laverne and Banyan Tree nor its associates make any recommendation or warranty concerning the accuracy or reliability or completeness of the information or the performance of the companies referred to in this document. Past performance is not indicative of future performance. Any opinions and or recommendations expressed in this material are subject to change without notice and, Laverne and Banyan Tree are not under any obligation to update or keep current the information contained herein. References made to third parties are based on information believed to be reliable but are not guaranteed as being accurate.
Laverne and Banyan Tree and its respective officers may have an interest in the securities or derivatives of any entities referred to in this material. Laverne and Banyan Tree do and seek to do business with companies that are the subject of its research reports. The analyst(s) hereby certify that all the views expressed in this report accurately reflect their personal views about the subject investment theme and/or company securities.
Although every attempt has been made to verify the accuracy of the information contained in the document, liability for any errors or omissions (except any statutory liability which cannot be excluded) is specifically excluded by Laverne and Banyan Tree, its associates, officers, directors, employees, and agents. Except for any liability which cannot be excluded, Laverne and Banyan Tree, its directors, employees and agents accept no liability or responsibility for any loss or damage of any kind, direct or indirect, arising out of the use of all or any part of this material. Recipients of this document agree in advance that Laverne and Banyan Tree are not liable to recipients in any matters whatsoever otherwise; recipients should disregard, destroy or delete this document. All information is correct at the time of publication. Laverne and Banyan Tree do not guarantee reliability and accuracy of the material contained in this document and are not liable for any unintentional errors in the document.
The securities of any company(ies) mentioned in this document may not be eligible for sale in all jurisdictions or to all categories of investors. This document is provided to the recipient only and is not to be distributed to third parties without the prior consent of Laverne and Banyan Tree.